This activity series presents the common challenges of diagnosing and managing progressive fibrotic interstitial lung disease subtypes of IPF and SSc-ILD . There is at present no cure for IPF or SSc-ILD and existing treatments focus on delaying disease progression, controlling symptoms and preventing complications.

Successful diagnosis of EGPA begins with a physician’s understanding of the HESs and ability to distinguish EGPA from other causes of eosinophilia and eosinophilic lung disease.

Gain insights into the importance of early diagnosis and early highly efficacious treatment of PF-ILD to improve lung function and quality of life

Investigating Critical Issues in the Management of Patients with Severe Asthma

Biologic Therapies to Address the Overuse of Oral Corticosteroids in the Management of Severe Asthma

Idiopathic pulmonary fibrosis (IPF) is considered the classic presentation of the fibrotic interstitial lung diseases (ILDs).

This CME activity reviews how to utilize available clinical guidelines to accurately diagnose patients with severe asthma vs difficult-to-treat asthma

Wondering if you should alter medications for your patients with severe asthma? The activity now includes an important update on how to manage patients with severe asthma during COVID-19! Learn the latest recommendations about NSAIDs, steroids and nebulizers for patients with asthma and COVID-19.